Tepezza warning label unlikely to have any impact on Horizon/Amgen deal - analyst
hapabapa
The new warning label on Horizon Therapeutics' (NASDAQ:HZNP) Tepezza drug over potential hearing impairment is unlikely to have any impact on Horizon's planned sale to Amgen (NASDAQ:AMGN). 
"We doubt this has any impact on the AMGN-HZNP deal as this was well known as we state above and hasn't really changed prescribing of Tepezza," Wells Fargo analyst Derek Archila wrote in a note on Thursday. "We'd think in AMGN's diligence process, this would have been looked at and clearly they proceeded with the deal."
Horizon (HZNP) shares ticked down 0.3% on Friday after dropping almost 2% on the news of the warning label on Thursday.
"While HZNP shares are weak on the news, we don't think the warning in the label changes much fundamentally nor increases the risk of the deal breaking," Archila added.
Tepezza is Horizon's best-selling drug and earned $405.3M in Q1 2023.
More on Horizon Therapeutics

Amgen, FTC said there are no ongoing talks, though open to settlement over Horizon
FTC Surprise Challenge Of Amgen's Acquisition Of Horizon Therapeutics
Amgen: Questioning The Horizon Therapeutics Acquisition